J&J’s (JNJ) stock has declined 6.4% in the past three months. J&J faces several challenges, including slowing sales in the MedTech segment, loss of exclusivity of its blockbuster drug, Stelara, and uncertainty around the talc lawsuits, among others.In addition to that, broader market uncertainties and a volatile macroeconomic environment continue to hurt the stock.The sky-high tariffs imposed by the United States and retaliatory tariffs by China and some other countries have been affecting global stock mark ...

Amgen’s (AMGN) stock has declined 10.4% in the past three months. A lot of this price decline is related to the broader macroeconomic uncertainty.Stocks have been on a roller-coaster ride since President Trump unveiled sky-high tariffs in early April and China came up with retaliatory tariffs. Last week, China and the United States struck a deal that eased trade tensions and resulted in a stock market recovery. Though the massive tariffs imposed by the United States and retaliatory tariffs by China and some ...